Travere Therapeutics(TVTX)
Focus: Travere Therapeutics is a publicly traded mid-cap biotech focused on rare kidney diseases and rare metabolic disorders with a commercial portfolio anchored by FILSPARI (sparsentan). The company operates at 201-500 employees with a specialty in small molecules and biologics across nephrology and rare disease indications.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
201-500
Open Jobs
16+3 this month
Stable — net +3 jobs in 30d
6 added, 3 removed. Backfill posture.
Should You Work at Travere Therapeutics?
AI assessmentBest suited for mission-driven professionals in nephrology/rare disease who can tolerate balance-sheet volatility for the opportunity to shape multiple rare disease launches in a focused, specialized organization.
Why Work Here
- Single approved asset (FILSPARI) with clear market focus: peak-stage drug generating $145M revenue (FY2025) in rare kidney disease with 5-year patent runway to 2030
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
1 in 5yr
FILSPARI
Hiring
Stable
Revenue
$145M
Key Products
Peak
Help build intelligence for Travere Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.